Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

• DOI: 10.1007/s40801-024-00427-0
• Publication Date: 2024-05-10T07:02:09Z
• Authors: Ee Vien Low; Hoon Shien Teh; Nicholas Yee Lian...; Suresh Kumar Chid...; Mohan Dass Pathma...; Wee Ric Kim; Wei Jia Lee; Zhi Wei Teh; Maheshwara Rao Ap...; Shahanizan Mohd Zin; Faizah Muhamad Zin; Samha Bashirah Mo...; Mastura Ismail; Azah Abdul Samad; Kalaiarasu M. Pea...
• Keywords: Ritonavir

Nirmatrelvir/ritonavir was administered orally to manage mild moderate symptoms of COVID-19 in adult patients. The objectives this study were (i) evaluate the cost-effectiveness prescribing nirmatrelvir/ritonavir within 5 days a illness order avert hospitalization 30-day period Malaysia setting; (ii) determine how variations pricing and rates will affect nirmatrelvir/ritonavir. related determined using 1 propensity score-matched real-world data from 14 July 2022 November 2022. To total per-person costs COVID-19, we added cost drug (nirmatrelvir/ritonavir or control), clinic visits inpatient care. Incremental ratio (ICER) per averted calculated. Our cohort included 31,487 rate 30 found be 0.35% for group treated with nirmatrelvir/ritonavir, 0.52% control group. an additional MYR 1,625.72 (USD 358.88) patient. This treatment also resulted reduction 0.17% risk hospitalization, which corresponded ICER 946,801.26 209,006.90) averted. In Malaysia, where vaccination high, has been shown beneficial outpatient adults who have factors; however, it only marginally effective against healthy during Omicron period.